Brands Capitalize on Creative with Advances in the Ad-Lib.io Platform
12.7.2022 16:00:00 EEST | Business Wire | Press release
Ad-Lib.io, a Smartly.io company and a leading next-generation Creative Management Platform (CMP), announced today the release of the next generation of Personalize™, Ad-Lib.io’s award-winning cookieless platform for creative management, media alignment and creative intelligence all in one place. Personalize 2.0 delivers breakthrough capabilities to accelerate and scale campaign activation while ensuring brand governance and improved campaign addressability cross-channel.
As a result of these advances, advertisers are experiencing a range of ROAS benefits, including:
- 28% reduction in time required to link media and creative strategies in a single digital workspace,
- 4x faster campaign builds with on-brand assets, published and approved automatically,
- 85% fewer clicks to build personalized variants for every audience in their media plan, and
- Up to a week’s advance notice prior to the onset of campaign fatigue, thanks to AI-driven modeling, along with the creative data insights to tune performance at the variant level.
“Scaling campaigns significantly while comfortably reducing production time has been simply delightful,” said Barbara Piras, Group Head of Digital Marketing at TUI Group. “Adding Ad-Lib.io’s technology to our marketing workflow has opened a new world of creative possibilities I’m excited to explore in the future.”
“Our hyperlocal marketing strategy has been instrumental to our success, and Ad-Lib.io is a key partner in helping us scale our reach and creative effectiveness in record time,” said Dean Weaving, Director of Brand Media Operations at Deliveroo. “Their platform has brought our creative and media teams together at a high level of collaboration and coordination, time and time again. We look forward to continuing our work, leveraging their platform, to bring the same relevant, on-target advertising to a multitude of highly differentiated localities.”
“According to a recent WBR Insights survey, only 10% of advertisers felt that their creative and media teams were aligned. This disconnect leads to a number of inefficiencies and sub-optimal results, and it is a core challenge addressed by our platform,” said Oli Marlow Thomas, Ad-Lib.io Founder. “Our goal is to transform the creative production process into one that is easier, faster, more collaborative, data-advised and better aligned to media strategies.”
With Personalize 2.0, advertisers can now execute multi-market activations across channels in fewer steps, integrate with leading media platforms to instantly pull in target audiences and publish approved creatives while reducing the risk of creative rejection. Advertisers can also build targeted creative campaigns and test and learn strategies at scale in minutes, across display, video and social. AI can be leveraged at every step along the way, from asset cropping for quick and easy image editing across channels and formats, to fatigue alerts to prevent premature decline in campaign performance. Best of all, in-line performance reporting reduces the campaign optimization effort to just a few clicks.
Personalize 2.0 is immediately available. Click here for more information on Ad-Lib.io and the Smartly.io family of creative effectiveness capabilities.
About Ad-lib.io
Ad-Lib.io, a Smartly.io company, provides the leading next-generation Creative Management Platform for marketers at the world’s largest brands to enable them to scale their digital creative. Ad-Lib.io connects creative and media workflows using intelligent automation, making it easy and fast to produce and optimize relevant ad creative across all digital channels. These ads are 60% more cost-efficient to produce, according to Ad-LIb.io’s customers, including TUI, Estee Lauder, IG, Pizza Hut and other global brands.. Recently acquired by Smartly.io, Ad-Lib.io was founded by former Google executives who understood the need to close the wide gap between creative concepts and digital media execution.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220712005295/en/
Contact information
Dina Magdovitz
smartly.io@pancomm.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 17:00:00 EEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 16:34:00 EEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release
Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release
Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
